

# Christian K. Roy, PhD

Christian K. Roy

20256-05-21



- Greater Boston Area, MA
- [christiankroy@pm.me](mailto:christiankroy@pm.me)
- [Website](#)
- [LinkedIn](#)
- [GitHub](#)
- [ORCID](#)

With over 20 years of expertise in pharmaceuticals, biotech, and academic research, I specialize in leveraging large-scale datasets to optimize clinical trial insights, execution, and outcomes. Thriving in collaborative environments, my strategic leadership and technical proficiency have consistently driven innovation across global organizations while delivering high-quality patient outcomes. As a results-driven professional with a deep passion for data science and translational research, I am committed to advancing data-driven solutions that enable informed decision-making and foster impactful collaborative environments.

## Core Competencies

- RNA Biology, Oncology, Immunotherapy
  - Multi-Omics Data Integration
  - Translational Biomarker Development
  - Computational Oncology & Cell/Gene Therapy
  - Cloud Infrastructure & Pipeline Automation (AWS, Nextflow)
  - Predictive Modeling & Data Visualization
  - Team Leadership & Cross-Functional Collaboration
  - Clinical Trial Data Management & EDC Tools
  - Scientific Communication & Stakeholder Engagement
- 

## Experience

### **Affini-T Therapeutics (Watertown, MA)**

*Associate Director: Precision and Translational Medicine and Computational Biology*  
December 2021 – Present

- Led multidisciplinary initiatives at a cell and gene therapy start-up, successfully driving translational and computational strategies supporting [AFNT-211](#), a multi-site single-arm TCR-T clinical trial in solid tumors.
- Led a diverse Computational team of 1 FTE, 3 contractors, 2 associated Discovery scientists, 2 academic consultants, and multiple vendors.
- Integrated and harmonized complex multi-source clinical, translational, and manufacturing data types, including EDC, CMC, ctDNA, PK/PD, flow cytometry, scRNA-seq, and cytokines.
- Designed and maintained interactive dashboards that increased trial data accessibility, stakeholder engagement, and decision making.
- Developed statistical models to predict responses based on enrollment criteria and improve patient trial response rates.
- Conducted site visits engaging clinical investigators, leading to increased enrollment rates and enhanced site feedback incorporation.
- Contributed patient population analysis based on preclinical experiments for inclusion in IND filings.
- Created a novel patient population estimation algorithm based on HLA and mutation frequencies (see [Roy2025](#) for HLA component).
- Leveraged public and proprietary datasets to assess HLA Loss of Heterozygosity impacts on therapy efficacy (see [Poster](#)).

- Architected and maintained a multi-account AWS cloud infrastructure supporting both Discovery and Clinical programs.
- Championed deployment of computational workflow management systems enabling scalable, reproducible analysis pipelines.
- Supported Discovery and Preclinical activities from 2021–2024, and after a RIF, insured continuity and knowledge retention.
- Led efforts in TCR sequencing analysis and novel target identification (oncogene antigens, private neoantigens, ncRNAs, cryptic peptides).

---

## **Takeda Oncology (Cambridge, MA)**

**Principal Scientist: Discovery Translational Science and Computational Oncology**  
October 2017 – December 2021

- Directed Computational Oncology support for multiple cell therapy discovery projects.
- Collaborated closely with cell therapy teams to design and analyze preclinical translational experiments, informing clinical strategy.
- Led pilot evaluations of spatial transcriptomics platforms, informing technology adoption across Discovery.
- Managed three direct reports, fostering skill development and productivity improvements.
- Spearheaded optimization of cell therapy combinations involving armoring, target selection, platform delivery, and patient population stratification (Project “Square”).
- Identified novel cell therapy targets with an emphasis on clinical relevance and competitive landscape.
- Played key role in interview panels and onboarding, enhancing team cohesion and technical ramp-up.
- Integrated public and proprietary genomic and proteomic datasets to identify tumor-associated antigens uniquely overexpressed in lung cancer.
- Supported GI-DDU scientists with RNA-Seq and scRNA-Seq dataset analyses and external therapeutic platform designs.
- Developed, validated, and disseminated single-cell RNA-seq pipelines, enabling reproducible data analysis across platforms.
- Founded and led internal working group focused on scRNA-seq technology awareness and best practices.
- Revitalized scientific computing environments, facilitating cloud migration and elastic resource scaling.
- Oversaw NGS outsourcing operations for multiple teams, ensuring cost efficiency and data quality.

- Core team member piloting Apple MacBooks deployment across Discovery, supporting IT transition.

---

## **Ohana Biosciences/VL34 Inc (Cambridge, MA)**

*Senior Scientist, Computational Biology*

October 2016 – October 2017

- Provided foundational scientific analysis culminating in publication in [Science](#).
- Designed and implemented AWS-based collaborative computing environments for large-scale genomics.
- Performed exome sequencing of key commercial dairy bulls to identify novel tissue-specific protein isoforms.
- Developed scalable pipelines for transcript reconstruction and whole chromosome haplotype phasing across species.
- Led multi-species genomic analyses interpreting whole genome, exome, and single-cell sequencing.
- Assembled tissue- and cell-type-specific transcriptomes integrating publicly available datasets.
- Integrated RNA-Seq data from >15 distinct bovine tissues to generate comprehensive gene and transcript annotations.
- Fostered relationships with dairy farmers innovating in cattle genetics, integrating phenotype and genotype datasets.
- Developed candidate evaluation portals integrating multi-omic data to optimize candidate selection efficiency.

---

## **Takeda Oncology (Cambridge, MA)**

*Scientist 2, Computational Biologist*

October 2014 – October 2016

- Advanced oncology small molecule drug development using HTS data from public and in-house sources.
- Conducted comprehensive bioinformatic assessments covering expression profiles, indication suitability, mutations, and other omic features.
- Identified early translational strategies applying tool molecule responses across hundreds of cell lines.

- Selected translationally appropriate *in vitro* and *in vivo* models for target validation.
  - Conducted genome-wide screening for antibody drug conjugate targets.
  - Analyzed treatment-induced differential gene expression in models.
  - Enhanced department-wide computational biology capabilities with command-line and cloud computing adoption.
- 

## **Voyager Therapeutics (Cambridge, MA)**

*Consultant, Computational Biology Vector Design Group*

June 2014 – October 2014

- Built AWS cloud-based computational biology HTS analysis environment.
  - Directed AAV vector design leveraging public small RNA-Seq datasets.
  - Analyzed and interpreted company-generated HTS data.
- 

## **Graduate School (Worcester, MA)**

*Graduate Student*

See [Education](#) for details. September 2007 – June 2014

---

## **Genzyme (Framingham, MA)**

*Research Associate, Bioanalytical Development Group*

April 2004 – September 2007

- Developed GLP/GMP biochemical assays for recombinant protein clinical trials.
- Engineered HPLC assays for protein glycosylation quantification.
- Developed qPCR assays to monitor viral contamination in production cell lines.

*Research Intern, Bioanalytical Development Group*

Summer 2003

- Supported preclinical and clinical research via IEF assays and ELISAs.
-

## **Achillion Pharmaceuticals (New Haven, CT)**

*Research Internship*

Summer 2002

- Conducted ELISAs and cell culture supporting small molecule screening.

---

---

## **Education**

### **University of Massachusetts Medical School (Worcester, MA)**

- Graduate School of Biomedical Sciences
- RNA Therapeutics Institute and Howard Hughes Medical Institute
- Doctor of Philosophy, Biochemistry and Molecular Pharmacology
- Advisors: [Melissa J. Moore](#) & [Phillip D. Zamore](#)
- September 2007 – May 2014
- Developed novel ligation-based assays for long RNAs (1,000–10,000 nt) ([eLife 2015](#))
- Characterized piRNA-producing lncRNAs using multi-omic HTS data ([Molecular Cell 2013](#))

### **Worcester Polytechnic Institute (Worcester, MA)**

- Bachelor of Science with High Distinction
- September 2000 – May 2004
- Major: [Biology & Biotechnology](#), Minor: Management

---

## Patents, Publications, Software

You can also browse my [ORCID profile](#)

- **Regional Distribution of HLA Frequencies in the USA: Implications for TCR-Based Therapies** *Journal for ImmunoTherapy of Cancer* (April 2025)  
**Christian K. Roy**, Tomasz Sewastianik, Ileana Saenz, Gregory J. Opiteck, Sean Stagg, Martin Maiers, Dirk Nagorsen
- **CensusHLA**: R Package in support of Roy 2025 JITC  
Available from: [Zenodo](#) and [GitHub](#)
- **Allele-Specific HLA LOH Impacts Survival of Colorectal and Non-Small Cell Lung Cancer Patients** (submitted)  
*Journal for ImmunoTherapy of Cancer* (~2025)  
Tomasz Sewastianik, **Christian Roy**, Michael Gormally, Meagan Montesion, Patrick Halvey, Aastha Jindal, Hubert Lam, Adam Schoenfeld, Christopher Klebanoff, Gregory Opiteck, Dirk Nagorsen
- **Human NLRC4 Expression Promotes Cancer Survival and Associates with Type I Interferon Signaling and Immune Infiltration**  
*Journal of Clinical Investigation* (2024)  
Charlotte Domblides, Steven Crampton, Hong Liu, Juliet M. Bartleson, Annie Nguyen, Claudia Champagne, Emily E. Landy, et al.
- **Widespread Haploid-Biased Gene Expression Enables Sperm-Level Natural Selection**  
*Science* (March 2021)  
Kunal Bhutani, Katherine Stansifer, Simina Ticau, Lazar Bojic, Chloe Villani, Joanna Slisz, Claudia Cremers, **Christian Roy**, Jerry Donovan, Brian Fiske, Robin Friedman
- **Subsets of Mononuclear Phagocytes Are Enriched in the Inflamed Colons of Patients with IBD**  
*BMC Immunology* (November 2019)  
Hong Liu, Suryasarathi Dasgupta, Yu Fu, Brandi Bailey, **Christian Roy**, Eric Lightcap, Benjamin Faustin
- **Assessing Long-Distance RNA Sequence Connectivity via RNA-Templated DNA-DNA Ligation**  
*eLife* (April 2015)  
**Christian K. Roy**, Sarah Olson, Brenton R. Graveley, Phillip D. Zamore, Melissa J. Moore
- **Deducing Exon Connectivity by RNA-Templated DNA Ligation/Sequencing**  
*Patent* US8975019 B2 (March 2015)  
Phillip D. Zamore, Melissa J. Moore, **Christian K. Roy**

- **Putting the Pieces Together: Exons and piRNAs**  
*UMMS Dissertation* (May 2014)  
**Christian K. Roy**  
Available on [Github](#)
- **An Ancient Transcription Factor Initiates the Burst of piRNA Production during Early Meiosis in Mouse Testes**  
*Molecular Cell* (April 2013)  
X.Z. Li\*, **Christian K. Roy\***, X. Dong, E. Bolcun-Filas, J. Wang, B.W. Han, J. Xu, Melissa J. Moore, J.C. Schimenti, Z. Weng, Phillip D. Zamore (\*Equal contribution)
- **Defining piRNA Primary Transcripts**  
*Cell Cycle* (May 2013)  
X.Z. Li, **Christian K. Roy**, Melissa J. Moore, Phillip D. Zamore
- **UPF1 Is Crucial for the Infectivity of Human Immunodeficiency Virus Type 1 Progeny Virions**  
*Journal of Virology* (August 2013)  
A.K.P. Serquiña, R.D. Suman, E. Popova, O.A. Ojelabi, **Christian K. Roy**, H.G. Göttinger

---

## Presentations

Conference / Event (Date)	Work Presented	Link
American Society for Histocompatibility and Immunogenetics (ASHI) Annual Meeting, Anaheim, CA (2024)	<i>Poster</i> : Integrating US Census Demographic Data with HLA Frequencies to Accelerate Targeted Cell Therapy Patient Enrollment	<a href="#">Poster</a>
<a href="#">American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Baltimore (2024)</a>	<i>Poster</i> : Loss of Heterozygosity is Low for Specific HLA Alleles in Cancer Patients with Driver Mutations	<a href="#">Poster</a>
Gordon Conference: The Biology Of Post-Transcriptional Gene Regulation, Newport, RI (2014)	<i>Short Talk</i> : Assessing long-distance RNA sequence connectivity via RNA-templated DNA-DNA ligation	



Conference / Event (Date)	Work Presented	Link
17th Annual Meeting of the RNA Society, Ann Arbor, MI (2012)	<i>Poster</i> : “SeqZip—A versatile methodology for analyzing long RNAs” <b>Winner</b> - Nature Reviews Molecular Cell Biology Poster Prize	<a href="#">Poster</a>
Gordon Conference: The Biology Of Post-Transcriptional Gene Regulation, Newport, RI (2010)	<i>Poster</i> : “A novel technique to discover connectivity between distant alternatively spliced exons”	
UMass Medical School RNA Club, Worcester, MA (2009)	<i>Presentation</i> : “Uncovering connectivity between distant alternatively spliced exons”	

## Skills

### Translational

- Multi-omics data integration and translational biomarker development
- Modeling and prediction to improve clinical trial outcomes
- Assay contracting, vendor management, and clinical site relationship management
- Electronic Data Capture database analysis (e.g., Medidata Rave)

### Computational

- Cloud computing on Amazon Web Services (AWS)
- Advanced R programming with experience in complete Posit Suite (Workbench/Rstudio; Package Manager; Connect)
- High-throughput sequencing data analysis and pipeline automation (`nextflow`, `snakemake`)
- Version control and collaborative development (`git`, GitHub Enterprise)
- Software containerization and deployment (`docker`, AWS EKS)
- Single-cell RNA-seq processing and analysis (`Seurat`, Bioturing, `cellxgene`)
- UNIX/Linux/GNU environments (`bash`, `perl`, `R`, `sql*`, some `python`)
- Data visualization and reporting (`quarto`, `knitr`, `shiny`, `spotfire`)

## **Bench**

- Molecular biology and biochemical laboratory techniques
  - HTS library construction
  - Cell culture and spectrophotometry
  - High-performance liquid chromatography (HPLC)
  - Nucleic acid radioactive manipulation
-